1. Koob GF, Volkow ND. Neurobiology of addiction: a
neurocircuitry analysis. Lancet Psychiatry. 2016;3(8):760-73.
doi: 10.1016/s2215-0366(16)00104-8.
2. Bailey CP, Connor M. Opioids: cellular mechanisms of
tolerance and physical dependence. Curr Opin Pharmacol.
2005;5(1):60-8. doi: 10.1016/j.coph.2004.08.012.
3. Williams JT, Ingram SL, Henderson G, Chavkin C, von
Zastrow M, Schulz S, et al. Regulation of μ-opioid receptors:
desensitization, phosphorylation, internalization, and
tolerance. Pharmacol Rev. 2013;65(1):223-54. doi: 10.1124/
pr.112.005942.
4. Simonovska N, Chibishev A, Babulovska A, Pereska Z,
Jurukov I, Glasnovic M. Program of the university clinic of
toxicology, skopje, republic of macedonia in treatment of drug
addiction (buprenorfin treatment protocol). Mater Sociomed.
2011;23(4):232-4. doi: 10.5455/msm.2011.23.232-234.
5. Delargy I, Crowley D, Van Hout MC. Twenty years of the
methadone treatment protocol in Ireland: reflections on the
role of general practice. Harm Reduct J. 2019;16(1):5. doi:
10.1186/s12954-018-0272-4.
6. Judd LL, Marston MG, Attkisson C, Berrettini W, Buc NL,
Bunney BS, et al. Effective medical treatment of opiate
addiction. JAMA. 1998;280(22):1936-43.
7. Dubey AK, Handu SS, Mediratta PK. Suvorexant: The first
orexin receptor antagonist to treat insomnia. J Pharmacol
Pharmacother. 2015;6(2):118-21. doi: 10.4103/0976-
500x.155496.
8. Barson JR, Leibowitz SF. Hypothalamic neuropeptide
signaling in alcohol addiction. Prog Neuropsychopharmacol
Biol Psychiatry. 2016;65:321-9. doi: 10.1016/j.
pnpbp.2015.02.006.
9. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson
PE, et al. The hypocretins: hypothalamus-specific peptides
with neuroexcitatory activity. Proc Natl Acad Sci U S A.
1998;95(1):322-7. doi: 10.1073/pnas.95.1.322.
10. Ebrahim IO, Howard RS, Kopelman MD, Sharief MK,
Williams AJ. The hypocretin/orexin system. J R Soc Med.
2002;95(5):227-30. doi: 10.1177/014107680209500503.
11. Razavi BM, Hosseinzadeh H. A review of the role of
orexin system in pain modulation. Biomed Pharmacother.
2017;90:187-93. doi: 10.1016/j.biopha.2017.03.053.
12. Mahler SV, Moorman DE, Smith RJ, James MH, Aston-Jones
G. Motivational activation: a unifying hypothesis of orexin/
hypocretin function. Nat Neurosci. 2014;17(10):1298-303.
doi: 10.1038/nn.3810.
13. James MH, Mahler SV, Moorman DE, Aston-Jones G. A
decade of orexin/hypocretin and addiction: where are we
now? Curr Top Behav Neurosci. 2017;33:247-81. doi:
10.1007/7854_2016_57.
14. Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A. Orexin A in
the VTA is critical for the induction of synaptic plasticity and
behavioral sensitization to cocaine. Neuron. 2006;49(4):589-
601. doi: 10.1016/j.neuron.2006.01.016.
15. Harris GC, Wimmer M, Aston-Jones G. A role for lateral
hypothalamic orexin neurons in reward seeking. Nature.
2005;437(7058):556-9. doi: 10.1038/nature04071.
16. Harris GC, Wimmer M, Randall-Thompson JF, Aston-Jones G.
Lateral hypothalamic orexin neurons are critically involved
in learning to associate an environment with morphine
reward. Behav Brain Res. 2007;183(1):43-51. doi: 10.1016/j.
bbr.2007.05.025.
17. Bonifazi A, Del Bello F, Giorgioni G, Piergentili A, Saab E,
Botticelli L, et al. Targeting orexin receptors: recent advances
in the development of subtype selective or dual ligands for
the treatment of neuropsychiatric disorders. Med Res Rev.
2023;43(5):1607-67. doi: 10.1002/med.21959.
18. Cao M, Guilleminault C. Hypocretin and its emerging role as
a target for treatment of sleep disorders. Curr Neurol Neurosci
Rep. 2011;11(2):227-34. doi: 10.1007/s11910-010-0172-9.
19. Scammell TE, Winrow CJ. Orexin receptors: pharmacology
and therapeutic opportunities. Annu Rev Pharmacol
Toxicol. 2011;51:243-66. doi: 10.1146/annurevpharmtox-010510-100528.
20. Adeghate E. Orexins: tissue localization, functions, and its
relation to insulin secretion and diabetes mellitus. Vitam
Horm. 2012;89:111-33. doi: 10.1016/b978-0-12-394623-
2.00007-x.
21. Adam JA, Menheere PP, van Dielen FM, Soeters PB, Buurman
WA, Greve JW. Decreased plasma orexin-A levels in obese
individuals. Int J Obes Relat Metab Disord. 2002;26(2):274-6.
doi: 10.1038/sj.ijo.0801868.
22. Adamantidis A, de Lecea L. Sleep and metabolism: shared circuits, new connections. Trends Endocrinol Metab.
2008;19(10):362-70. doi: 10.1016/j.tem.2008.08.007.
23. Mieda M, Sakurai T. Overview of orexin/hypocretin system.
Prog Brain Res. 2012;198:5-14. doi: 10.1016/b978-0-444-
59489-1.00002-1.
24. Horvath TL, Peyron C, Diano S, Ivanov A, Aston-Jones G,
Kilduff TS, et al. Hypocretin (orexin) activation and synaptic
innervation of the locus coeruleus noradrenergic system. J
Comp Neurol. 1999;415(2):145-59.
25. van den Pol AN, Ghosh PK, Liu RJ, Li Y, Aghajanian GK,
Gao XB. Hypocretin (orexin) enhances neuron activity and
cell synchrony in developing mouse GFP-expressing locus
coeruleus. J Physiol. 2002;541(Pt 1):169-85. doi: 10.1113/
jphysiol.2002.017426.
26. Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes
S, et al. Orexin A activates locus coeruleus cell firing and
increases arousal in the rat. Proc Natl Acad Sci U S A.
1999;96(19):10911-6. doi: 10.1073/pnas.96.19.10911.
27. Rivas M, Ferreira A, Torterolo P, Benedetto L. Hypocretins,
sleep, and maternal behavior. Front Behav Neurosci.
2023;17:1184885. doi: 10.3389/fnbeh.2023.1184885.
28. Wang C, Wang Q, Ji B, Pan Y, Xu C, Cheng B, et al. The orexin/
receptor system: molecular mechanism and therapeutic
potential for neurological diseases. Front Mol Neurosci.
2018;11:220. doi: 10.3389/fnmol.2018.00220.
29. Guo Y, Wang HL, Xiang XH, Zhao Y. The role of glutamate
and its receptors in mesocorticolimbic dopaminergic regions
in opioid addiction. Neurosci Biobehav Rev. 2009;33(6):864-
73. doi: 10.1016/j.neubiorev.2009.02.005.
30. Gass JT, Olive MF. Glutamatergic substrates of drug addiction
and alcoholism. Biochem Pharmacol. 2008;75(1):218-65.
doi: 10.1016/j.bcp.2007.06.039.
31. McLaughlin J, See RE. Selective inactivation of the
dorsomedial prefrontal cortex and the basolateral amygdala
attenuates conditioned-cued reinstatement of extinguished
cocaine-seeking behavior in rats. Psychopharmacology (Berl).
2003;168(1-2):57-65. doi: 10.1007/s00213-002-1196-x.
32. Goldstein RZ, Volkow ND. Drug addiction and its
underlying neurobiological basis: neuroimaging evidence
for the involvement of the frontal cortex. Am J Psychiatry.
2002;159(10):1642-52. doi: 10.1176/appi.ajp.159.10.1642.
33. Pierce RC, Kalivas PW. A circuitry model of the expression
of behavioral sensitization to amphetamine-like
psychostimulants. Brain Res Brain Res Rev. 1997;25(2):192-
216. doi: 10.1016/s0165-0173(97)00021-0.
34. Goldman-Rakic PS. The physiological approach: functional
architecture of working memory and disordered cognition
in schizophrenia. Biol Psychiatry. 1999;46(5):650-61. doi:
10.1016/s0006-3223(99)00130-4.
35. Bouyer JJ, Park DH, Joh TH, Pickel VM. Chemical and
structural analysis of the relation between cortical inputs and
tyrosine hydroxylase-containing terminals in rat neostriatum.
Brain Res. 1984;302(2):267-75. doi: 10.1016/0006-
8993(84)90239-7.
36. Xi ZX, Stein EA. Blockade of ionotropic glutamatergic
transmission in the ventral tegmental area reduces
heroin reinforcement in rat. Psychopharmacology (Berl).
2002;164(2):144-50. doi: 10.1007/s00213-002-1190-3.
37. Acquas E, Di Chiara G. Depression of mesolimbic dopamine
transmission and sensitization to morphine during opiate
abstinence. J Neurochem. 1992;58(5):1620-5. doi: 10.1111/
j.1471-4159.1992.tb10033.x.
38. Alam MN, Kumar S, Bashir T, Suntsova N, Methippara MM,
Szymusiak R, et al. GABA-mediated control of hypocretinbut not melanin-concentrating hormone-immunoreactive
neurones during sleep in rats. J Physiol. 2005;563(Pt 2):569-
82. doi: 10.1113/jphysiol.2004.076927.
39. Georgescu D, Zachariou V, Barrot M, Mieda M, Willie JT,
Eisch AJ, et al. Involvement of the lateral hypothalamic
peptide orexin in morphine dependence and withdrawal.
J Neurosci. 2003;23(8):3106-11. doi: 10.1523/
jneurosci.23-08-03106.2003.
40. Yeoh JW, James MH, Jobling P, Bains JS, Graham BA, Dayas
CV. Cocaine potentiates excitatory drive in the perifornical/
lateral hypothalamus. J Physiol. 2012;590(16):3677-89. doi:
10.1113/jphysiol.2012.230268.
41. Rao Y, Mineur YS, Gan G, Wang AH, Liu ZW, Wu X, et al.
Repeated in vivo exposure of cocaine induces long-lasting
synaptic plasticity in hypocretin/orexin-producing neurons in
the lateral hypothalamus in mice. J Physiol. 2013;591(7):1951-
66. doi: 10.1113/jphysiol.2012.246983.
42. Korotkova TM, Sergeeva OA, Eriksson KS, Haas HL, Brown
RE. Excitation of ventral tegmental area dopaminergic and
nondopaminergic neurons by orexins/hypocretins. J Neurosci.
2003;23(1):7-11. doi: 10.1523/jneurosci.23-01-00007.2003.
43. Vittoz NM, Berridge CW. Hypocretin/orexin selectively
increases dopamine efflux within the prefrontal
cortex: involvement of the ventral tegmental area.
Neuropsychopharmacology. 2006;31(2):384-95. doi:
10.1038/sj.npp.1300807.
44. Ahmadi-Soleimani SM, Azizi H, Gompf HS, Semnanian
S. Role of orexin type-1 receptors in paragiganto-coerulear
modulation of opioid withdrawal and tolerance: a site specific
focus. Neuropharmacology. 2017;126:25-37. doi: 10.1016/j.
neuropharm.2017.08.024.
45. Narita M, Nagumo Y, Hashimoto S, Narita M, Khotib J,
Miyatake M, et al. Direct involvement of orexinergic systems
in the activation of the mesolimbic dopamine pathway
and related behaviors induced by morphine. J Neurosci.
2006;26(2):398-405. doi: 10.1523/jneurosci.2761-05.2006.
46. Baimel C, Borgland SL. Hypocretin modulation of druginduced synaptic plasticity. Prog Brain Res. 2012;198:123-
31. doi: 10.1016/b978-0-444-59489-1.00008-2.
47. Zarrabian S, Riahi E, Karimi S, Razavi Y, Haghparast A. The
potential role of the orexin reward system in future treatments
for opioid drug abuse. Brain Res. 2020;1731:146028. doi:
10.1016/j.brainres.2018.11.023.
48. Schmeichel BE, Herman MA, Roberto M, Koob GF. Hypocretin
neurotransmission within the central amygdala mediates
escalated cocaine self-administration and stress-induced
reinstatement in rats. Biol Psychiatry. 2017;81(7):606-15. doi:
10.1016/j.biopsych.2016.06.010.
49. Harvey JA. Cocaine effects on the developing brain: current
status. Neurosci Biobehav Rev. 2004;27(8):751-64. doi:
10.1016/j.neubiorev.2003.11.006.
50. James MH, Stopper CM, Zimmer BA, Koll NE, Bowrey
HE, Aston-Jones G. Increased number and activity of a
lateral subpopulation of hypothalamic orexin/hypocretin
neurons underlies the expression of an addicted state in
rats. Biol Psychiatry. 2019;85(11):925-35. doi: 10.1016/j.
biopsych.2018.07.022.
51. España RA, Oleson EB, Locke JL, Brookshire BR, Roberts
DC, Jones SR. The hypocretin-orexin system regulates
cocaine self-administration via actions on the mesolimbic
dopamine system. Eur J Neurosci. 2010;31(2):336-48. doi:
10.1111/j.1460-9568.2009.07065.x.
52. Borgland SL, Chang SJ, Bowers MS, Thompson JL,
Vittoz N, selectively promotes motivation for positive reinforcers.
J Neurosci. 2009;29(36):11215-25. doi: 10.1523/
jneurosci.6096-08.2009.
53. Gozzi A, Turrini G, Piccoli L, Massagrande M, Amantini D,
Antolini M, et al. Functional magnetic resonance imaging
reveals different neural substrates for the effects of orexin-1 and
orexin-2 receptor antagonists. PLoS One. 2011;6(1):e16406.
doi: 10.1371/journal.pone.0016406.
54. Hutcheson DM, Quarta D, Halbout B, Rigal A, Valerio E,
Heidbreder C. Orexin-1 receptor antagonist SB-334867
reduces the acquisition and expression of cocaine-conditioned
reinforcement and the expression of amphetamineconditioned reward. Behav Pharmacol. 2011;22(2):173-81.
doi: 10.1097/FBP.0b013e328343d761.
55. Prince CD, Rau AR, Yorgason JT, España RA. Hypocretin/
orexin regulation of dopamine signaling and cocaine selfadministration is mediated predominantly by hypocretin
receptor 1. ACS Chem Neurosci. 2015;6(1):138-46. doi:
10.1021/cn500246j.
56. Gentile TA, Simmons SJ, Barker DJ, Shaw JK, España RA,
Muschamp JW. Suvorexant, an orexin/hypocretin receptor
antagonist, attenuates motivational and hedonic properties
of cocaine. Addict Biol. 2018;23(1):247-55. doi: 10.1111/
adb.12507.
57. Muschamp JW, Hollander JA, Thompson JL, Voren G,
Hassinger LC, Onvani S, et al. Hypocretin (orexin) facilitates
reward by attenuating the antireward effects of its cotransmitter
dynorphin in ventral tegmental area. Proc Natl Acad Sci U S
A. 2014;111(16):E1648-55. doi: 10.1073/pnas.1315542111.
58. Foltin RW, Evans SM. Hypocretin/orexin antagonists decrease
cocaine self-administration by female rhesus monkeys.
Drug Alcohol Depend. 2018;188:318-27. doi: 10.1016/j.
drugalcdep.2018.04.018.
59. Fadel J, Deutch AY. Anatomical substrates of orexindopamine interactions: lateral hypothalamic projections to
the ventral tegmental area. Neuroscience. 2002;111(2):379-
87. doi: 10.1016/s0306-4522(02)00017-9.
60. Fadel J, Deutch AY. Anatomical substrates of orexindopamine interactions: lateral hypothalamic projections to
the ventral tegmental area. Neuroscience. 2002;111(2):379-
87. doi: 10.1016/s0306-4522(02)00017-9.
61. McPherson CS, Featherby T, Krstew E, Lawrence AJ.
Quantification of phosphorylated cAMP-response elementbinding protein expression throughout the brain of
amphetamine-sensitized rats: activation of hypothalamic
orexin A-containing neurons. J Pharmacol Exp Ther.
2007;323(3):805-12. doi: 10.1124/jpet.107.125732.
62. Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM,
Yanagisawa M, et al. Fos expression in orexin neurons varies
with behavioral state. J Neurosci. 2001;21(5):1656-62. doi:
10.1523/jneurosci.21-05-01656.2001.
63. Quarta D, Valerio E, Hutcheson DM, Hedou G, Heidbreder
C. The orexin-1 receptor antagonist SB-334867 reduces
amphetamine-evoked dopamine outflow in the shell of
the nucleus accumbens and decreases the expression of
amphetamine sensitization. Neurochem Int. 2010;56(1):11-5.
doi: 10.1016/j.neuint.2009.08.012.
64. Quarta D, Valerio E, Hutcheson DM, Hedou G, Heidbreder
C. The orexin-1 receptor antagonist SB-334867 reduces
amphetamine-evoked dopamine outflow in the shell of
the nucleus accumbens and decreases the expression of
amphetamine sensitization. Neurochem Int. 2010;56(1):11-5.
doi: 10.1016/j.neuint.2009.08.012.
65. Tung LW, Lu GL, Lee YH, Yu L, Lee HJ, Leishman E, et al.
Orexins contribute to restraint stress-induced cocaine relapse
by endocannabinoid-mediated disinhibition of dopaminergic
neurons. Nat Commun. 2016;7:12199. doi: 10.1038/
ncomms12199.
66. Bentzley BS, Aston-Jones G. Orexin-1 receptor signaling
increases motivation for cocaine-associated cues. Eur J
Neurosci. 2015;41(9):1149-56. doi: 10.1111/ejn.12866.
67. Gentile TA, Simmons SJ, Watson MN, Connelly KL, Brailoiu E,
Zhang Y, et al. Effects of suvorexant, a dual orexin/hypocretin
receptor antagonist, on impulsive behavior associated with
cocaine. Neuropsychopharmacology. 2018;43(5):1001-9.
doi: 10.1038/npp.2017.158.
68. Levy KA, Brodnik ZD, Shaw JK, Perrey DA, Zhang Y, España
RA. Hypocretin receptor 1 blockade produces bimodal
modulation of cocaine-associated mesolimbic dopamine
signaling. Psychopharmacology (Berl). 2017;234(18):2761-
76. doi: 10.1007/s00213-017-4673-y.
69. Flores Á, Maldonado R, Berrendero F. The hypocretin/
orexin receptor-1 as a novel target to modulate cannabinoid
reward. Biol Psychiatry. 2014;75(6):499-507. doi: 10.1016/j.
biopsych.2013.06.012.
70. Khoo SY, McNally GP, Clemens KJ. The dual orexin receptor
antagonist TCS1102 does not affect reinstatement of nicotineseeking. PLoS One. 2017;12(3):e0173967. doi: 10.1371/
journal.pone.0173967.
71. Plaza-Zabala A, Flores Á, Maldonado R, Berrendero
F. Hypocretin/orexin signaling in the hypothalamic
paraventricular nucleus is essential for the expression of
nicotine withdrawal. Biol Psychiatry. 2012;71(3):214-23. doi:
10.1016/j.biopsych.2011.06.025.
72. Brown RM, Lawrence AJ. Ascending orexinergic pathways
and alcohol-seeking. Curr Opin Neurobiol. 2013;23(4):467-
72. doi: 10.1016/j.conb.2013.02.014.
73. Lawrence AJ. Regulation of alcohol-seeking by orexin
(hypocretin) neurons. Brain Res. 2010;1314:124-9. doi:
10.1016/j.brainres.2009.07.072.
74. Mahler SV, Smith RJ, Moorman DE, Sartor GC, Aston-Jones G.
Multiple roles for orexin/hypocretin in addiction. Prog Brain
Res. 2012;198:79-121. doi: 10.1016/b978-0-444-59489-
1.00007-0.
75. Baimel C, Bartlett SE, Chiou LC, Lawrence AJ, Muschamp
JW, Patkar O, et al. Orexin/hypocretin role in reward:
implications for opioid and other addictions. Br J Pharmacol.
2015;172(2):334-48. doi: 10.1111/bph.12639.
76. Olney JJ, Navarro M, Thiele TE. Binge-like consumption
of ethanol and other salient reinforcers is blocked by
orexin-1 receptor inhibition and leads to a reduction of
hypothalamic orexin immunoreactivity. Alcohol Clin Exp
Res. 2015;39(1):21-9. doi: 10.1111/acer.12591.
77. Morganstern I, Chang GQ, Barson JR, Ye Z, Karatayev O,
Leibowitz SF. Differential effects of acute and chronic ethanol
exposure on orexin expression in the perifornical lateral
hypothalamus. Alcohol Clin Exp Res. 2010;34(5):886-96. doi:
10.1111/j.1530-0277.2010.01161.x.
78. Lawrence AJ, Cowen MS, Yang HJ, Chen F, Oldfield B.
The orexin system regulates alcohol-seeking in rats. Br J
Pharmacol. 2006;148(6):752-9. doi: 10.1038/sj.bjp.0706789.
79. Srinivasan S, Simms JA, Nielsen CK, Lieske SP, Bito-Onon JJ,
Yi H, et al. The dual orexin/hypocretin receptor antagonist,
almorexant, in the ventral tegmental area attenuates ethanol
self-administration. PLoS One. 2012;7(9):e44726. doi:
10.1371/journal.pone.0044726.
80. Mayannavar S, Rashmi KS, Rao YD, Yadav S, Ganaraja B.
Effect of Orexin A antagonist (SB-334867) infusion into the nucleus accumbens on consummatory behavior and alcohol
preference in Wistar rats. Indian J Pharmacol. 2016;48(1):53-
8. doi: 10.4103/0253-7613.174528.
81. Barson JR, Ho HT, Leibowitz SF. Anterior thalamic
paraventricular nucleus is involved in intermittent access
ethanol drinking: role of orexin receptor 2. Addict Biol.
2015;20(3):469-81. doi: 10.1111/adb.12139.
82. Moorman DE, James MH, Kilroy EA, Aston-Jones G. Orexin/
hypocretin-1 receptor antagonism reduces ethanol selfadministration and reinstatement selectively in highlymotivated rats. Brain Res. 2017;1654(Pt A):34-42. doi:
10.1016/j.brainres.2016.10.018.
83. Dhaher R, Hauser SR, Getachew B, Bell RL, McBride WJ,
McKinzie DL, et al. The orexin-1 receptor antagonist SB334867 reduces alcohol relapse drinking, but not alcoholseeking, in alcohol-preferring (P) rats. J Addict Med.
2010;4(3):153-9. doi: 10.1097/ADM.0b013e3181bd893f.
84. Lopez MF, Moorman DE, Aston-Jones G, Becker HC. The
highly selective orexin/hypocretin 1 receptor antagonist
GSK1059865 potently reduces ethanol drinking in ethanol
dependent mice. Brain Res. 2016;1636:74-80. doi: 10.1016/j.
brainres.2016.01.049.
85. Sanchez-Alavez M, Benedict J, Wills DN, Ehlers CL. Effect of
suvorexant on event-related oscillations and EEG sleep in rats
exposed to chronic intermittent ethanol vapor and protracted
withdrawal. Sleep. 2019;42(4):zsz020. doi: 10.1093/sleep/
zsz020.
86. Hoch M, Hay JL, Hoever P, de Kam ML, te Beek ET, van
Gerven JM, et al. Dual orexin receptor antagonism by
almorexant does not potentiate impairing effects of alcohol
in humans. Eur Neuropsychopharmacol. 2013;23(2):107-17.
doi: 10.1016/j.euroneuro.2012.04.012.
87. Steiner MA, Lecourt H, Strasser DS, Brisbare-Roch C, Jenck
F. Differential effects of the dual orexin receptor antagonist
almorexant and the GABA(A)-α1 receptor modulator zolpidem,
alone or combined with ethanol, on motor performance in
the rat. Neuropsychopharmacology. 2011;36(4):848-56. doi:
10.1038/npp.2010.224.
88. Calipari ES, España RA. Hypocretin/orexin regulation
of dopamine signaling: implications for reward and
reinforcement mechanisms. Front Behav Neurosci. 2012;6:54.
doi: 10.3389/fnbeh.2012.00054.
89. Farahimanesh S, Zarrabian S, Haghparast A. Role of orexin
receptors in the ventral tegmental area on acquisition
and expression of morphine-induced conditioned place
preference in the rats. Neuropeptides. 2017;66:45-51. doi:
10.1016/j.npep.2017.08.003.
90. Hooshmandi M, Hosseinmardi N, Janahmadi M, Khakpai F,
Rohampour K, Doostmohammadi J. Antagonism of orexin
type-1 receptors (OX1Rs) attenuates naloxone-precipitated
morphine withdrawal syndrome in rat dorsal hippocampus.
Pharmacol Biochem Behav. 2017;158:39-48. doi: 10.1016/j.
pbb.2017.06.001.
91. Sharf R, Sarhan M, Dileone RJ. Orexin mediates the expression
of precipitated morphine withdrawal and concurrent
activation of the nucleus accumbens shell. Biol Psychiatry.
2008;64(3):175-83. doi: 10.1016/j.biopsych.2008.03.006.
92. Davoudi M, Azizi H, Mirnajafi-Zadeh J, Semnanian S. The
blockade of GABAA receptors attenuates the inhibitory effect
of orexin type 1 receptors antagonist on morphine withdrawal
syndrome in rats. Neurosci Lett. 2016;617:201-6. doi:
10.1016/j.neulet.2016.02.022.
93. Aghajani N, Pourhamzeh M, Azizi H, Semnanian S. Central
blockade of orexin type 1 receptors reduces naloxone
induced activation of locus coeruleus neurons in morphine
dependent rats. Neurosci Lett. 2021;755:135909. doi:
10.1016/j.neulet.2021.135909.
94. Fakhari M, Azizi H, Semnanian S. Central antagonism of orexin
type-1 receptors attenuates the development of morphine
dependence in rat locus coeruleus neurons. Neuroscience.
2017;363:1-10. doi: 10.1016/j.neuroscience.2017.08.054.
95. Mousavi Y, Azizi H, Mirnajafi-Zadeh J, Javan M, Semnanian
S. Blockade of orexin type-1 receptors in locus coeruleus
nucleus attenuates the development of morphine dependency
in rats. Neurosci Lett. 2014;578:90-4. doi: 10.1016/j.
neulet.2014.06.038.
96. Boutrel B, Steiner N, Halfon O. The hypocretins and the
reward function: what have we learned so far? Front Behav
Neurosci. 2013;7:59. doi: 10.3389/fnbeh.2013.00059.
97. Schmeichel BE, Barbier E, Misra KK, Contet C, Schlosburg JE,
Grigoriadis D, et al. Hypocretin receptor 2 antagonism dosedependently reduces escalated heroin self-administration in
rats. Neuropsychopharmacology. 2015;40(5):1123-9. doi:
10.1038/npp.2014.293.
98. Esmaili-Shahzade-Ali-Akbari P, Hosseinzadeh H, Mehri
S. Effect of suvorexant on morphine tolerance and
dependence in mice: role of NMDA, AMPA, ERK and CREB
proteins. Neurotoxicology. 2021;84:64-72. doi: 10.1016/j.
neuro.2021.02.005.
99. Huhn AS, Finan PH, Gamaldo CE, Hammond AS, Umbricht A,
Bergeria CL, et al. Suvorexant ameliorated sleep disturbance,
opioid withdrawal, and craving during a buprenorphine
taper. Sci Transl Med. 2022;14(650):eabn8238. doi: 10.1126/
scitranslmed.abn8238.
100. Łupina M, Tarnowski M, Baranowska-Bosiacka I, Talarek S,
Listos P, Kotlińska J, et al. SB-334867 (an orexin-1 receptor
antagonist) effects on morphine-induced sensitization in
mice-a view on receptor mechanisms. Mol Neurobiol.
2018;55(11):8473-85. doi: 10.1007/s12035-018-0993-0.
101. Hooshmand B, Azizi H, Javan M, Semnanian S. Intra-LC
microinjection of orexin type-1 receptor antagonist SB334867 attenuates the expression of glutamate-induced opiate
withdrawal like signs during the active phase in rats. Neurosci
Lett. 2017;636:276-81. doi: 10.1016/j.neulet.2016.10.051.
102. Ebrahimian F, Naghavi FS, Yazdi F, Sadeghzadeh F, Taslimi
Z, Haghparast A. Differential roles of orexin receptors
within the dentate gyrus in stress- and drug priming-induced
reinstatement of conditioned place preference in rats. Behav
Neurosci. 2016;130(1):91-102. doi: 10.1037/bne0000112.
103. Porter-Stransky KA, Bentzley BS, Aston-Jones G. Individual
differences in orexin-I receptor modulation of motivation for
the opioid remifentanil. Addict Biol. 2017;22(2):303-17. doi:
10.1111/adb.12323.
104. Berhow MT, Hiroi N, Nestler EJ. Regulation of ERK
(extracellular signal regulated kinase), part of the neurotrophin
signal transduction cascade, in the rat mesolimbic
dopamine system by chronic exposure to morphine or
cocaine. J Neurosci. 1996;16(15):4707-15. doi: 10.1523/
jneurosci.16-15-04707.1996.
105. Valjent E, Corvol JC, Pages C, Besson MJ, Maldonado
R, Caboche J. Involvement of the extracellular signalregulated kinase cascade for cocaine-rewarding
properties. J Neurosci. 2000;20(23):8701-9. doi: 10.1523/
jneurosci.20-23-08701.2000.
106. Valjent E, Pascoli V, Svenningsson P, Paul S, Enslen H, Corvol
JC, et al. Regulation of a protein phosphatase cascade allows
convergent dopamine and glutamate signals to activate ERK
in the striatum. Proc Natl Acad Sci U S A. 2005;102(2):491-6. doi: 10.1073/pnas.0408305102.
107. Shin HS, Cho HS, Sung KW, Yoon BJ. Orexin-A increases
cell surface expression of AMPA receptors in the striatum.
Biochem Biophys Res Commun. 2009;378(3):409-13. doi:
10.1016/j.bbrc.2008.11.051.
108. Guo Y, Feng P. OX2R activation induces PKC-mediated ERK
and CREB phosphorylation. Exp Cell Res. 2012;318(16):2004-
13. doi: 10.1016/j.yexcr.2012.04.015.
109. Carlezon WA Jr, Duman RS, Nestler EJ. The many faces of
CREB. Trends Neurosci. 2005;28(8):436-45. doi: 10.1016/j.
tins.2005.06.005.
110. Nestler EJ, Aghajanian GK. Molecular and cellular basis of
addiction. Science. 1997;278(5335):58-63. doi: 10.1126/
science.278.5335.58.
111. Riahi E, Khodagholi F, Haghparast A. Role of dorsal
hippocampal orexin-1 receptors in associating morphine
reward with contextual stimuli. Behav Pharmacol.
2013;24(4):237-48. doi: 10.1097/FBP.0b013e3283635ee9.
)